Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments ... which was recently approved in the United States as a treatment for some forms of ...

Northwell Health partnered with Stacker to examine how rising prices for healthy foods impact low-income families, using data ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments. Click to read why NVO stock is a Buy.

The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic approach to eating is more helpful.

January same-store sales increased 4.7% year-over-year NEWARK, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data ...

The failure favored Novo Nordisk’s arch-rival, Eli Lilly LLY, in the obesity ... in the United States. Novo Nordisk is trading at a premium to the industry, as seen in the chart below.

January same-store sales increased 4.7% year-over-year NEWARK, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- NRSInsights, a ...

Watch live as RFK Jr. faces questions from senators in his confirmation hearing as President Trump’s nominee to lead the Department of Health and Human Services.

Calculator - get your body fat percentage. Woolcott OO, Seuring T. Temporal trends in obesity defined by the relative fat mass (RFM) index among adults in the United States from 1999 to 2020: A ...